Retina
experience
redefined
RETINA EXPERIENCE
Our retina experience will redefine your retina experience
Our team has unmatched expertise and an impressive track record of innovation in retinal disease
clinical trials designed or led by our team
combined years of treating patients with retinal disease
treatment launches across retinal disease
DISEASE BURDEN
Retinal disease is one of the leading causes of blindness1,2
1.8M
Americans3
Wet Age-Related Macular Degeneration (AMD)
6.4M
Americans3
Non-Proliferative Diabetic Retinopathy (NPDR)
1.7M
Americans3
Diabetic Macular
Edema (DME)
TREATMENT BURDEN
Treatments for retinal disease create significant burden on patients and care partners4
Wet AMD treatment creates significant burden on patients and care partners4
Patient Burden
90% of patients currently require injections every 1-3 months, impacting and disrupting lives4,5
Care Partner Burden
Poor Long-Term Outcomes
Frequent injections may result in retinal fluid fluctuations and decreased adherence, which are associated with poor long-term outcomes6
REDEFINING TREATMENT
Ocular aims to transform the
treatment of retinal disease
We aim to reduce the therapeutic burden so more patients can stay on treatment...
in the hope of preserving vision for the long term.
AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is currently in Phase 3 clinical trials for wet AMD
DISEASE BURDEN
Retinal disease is one of the leading causes of blindness
WET AMD TREATMENT BURDEN
Current treatment imposes a significant burden on patients and care partners15
Patient Burden
90% of patients currently require injections every 1-3 months, impacting and disrupting lives14,19
Care Partner Burden
Up to 12 days off from work per year may be needed from care partners for treatment visits19
Poor Long-Term Outcomes
Frequent injections may result in decreased adherence and retinal fluid fluctuations, which are associated with poor long-term outcomes21
REDEFINING TREATMENT
Ocular aims to transform the treatment of retinal disease
We aim to reduce the therapeutic burden so more patients can stay on treatment…in the hope of preserving vision for the long term.
Ocular’s investigational therapy, AXPAXLITM (axitinib intravitreal hydrogel), also known as OTX-TKI, is currently in Phase 3 clinical trials for wet AMD
Read our
latest news
Explore our
pipeline
Learn about
upcoming events
References
1. Wang W, et al. Int J Mol Sci. 2018;19(6):1816. 2. Di Carlo E, et al. J Clin Med. 2021;10(15):3297. 3. Market Scope. 2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases. St. Louis, MO: Market Scope, LLC. 2024. 4. Gualino V, et al. J Fr Ophtalmol. 2020;43:1047-1053. 5. Market Scope. Ophthalmic Market Trends: Quarterly US Retina Edition. St. Louis, MO: Market Scope, LLC. 2025. 6. Evans RN, et al. JAMA Ophthalmol. 2020;138(10):1109.